CAPTIVATE
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
- NCT02910583 ↗
- Completed
- Pharmacyclics LLC.
- Deep
We haven't built an HCP commentary report on CAPTIVATE (ibrutinib plus venetoclax in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 40 newest of 233 indexed sources (Oct 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether the original regimen can be reused after relapse following fixed-duration therapy
- Whether treatment duration should differ for high-risk disease
- How MRD should guide treatment duration, including whether to stop at undetectable MRD
Also discussed: resistance mutations, IGHV status.
Indexed commentary on CAPTIVATE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 117 | |
| Podcasts | 72 | |
| X threads | 43 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions
- ibrutinib; venetoclax; Placebo
- Arms
- Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax · Experimental
- MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded) · Experimental
- MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded) · Placebo comparator
- MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label) · Experimental
- MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label) · Experimental
- Enrollment
- 323
- Primary outcomes
- MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants
- FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate
- Sponsor
- Pharmacyclics LLC. with Janssen Research & Development, LLC
- Start
- Sep 28, 2016
- Primary completion
- Nov 12, 2020
- Results posted
- Yes
- Registry record
- NCT02910583 · updated Sep 10, 2026
Publications
linked from the registry- Castonguay M, Anderson MA, Thompson P, Seymour JF. Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. Blood Adv. 2026 May 26;10(10):3357-3366. doi: 10.1182/bloodadvances.2026019871. PubMed 41843779
- Moreno C, Solman IG, Tam CS, Grigg A, Scarfo L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv. 2023 Sep 26;7(18):5294-5303. doi: 10.1182/bloodadvances.2023010236. PubMed 37315225
- Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021 Dec 1;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 7. PubMed 34618601